Endo’s president and chief executive officer designate Blaise Coleman told investors he was “honored and excited to lead Endo in its next phase,” as the US firm reported another full year of struggling sales for its US non-injectable Generics unit and another overall sizable financial loss.
Stepping up from the role of chief financial officer on 6 March to take over from Paul Campanelli, who will remain chairman of the company following his appointment by Endo’s board last November, Coleman faces several challenges, both internal and external, to steer Endo back to growth and profitability